Newcells Biotech joins StemBANCC consortium

Newcells Biotech has joined the StemBANCC project, a pan-EU consortium made up of major pharmaceutical and academe groups. StemBANCC’s goal is to generate 1,500 iPSC lines from 500 people, characterise them in terms of their genetic, protein, and metabolic profiles, and make them available to researchers for toxicology testing and disease modelling.

The raw materials for the project are largely skin and blood samples taken from patients with certain diseases, people who display adverse reactions to drugs, and healthy individuals. There is a strong focus on peripheral nervous system disorders (especially pain); central nervous system disorders (e.g. dementias); neuro-dysfunctional diseases (e.g. migraine, autism, schizophrenia, and bipolar disorder); and diabetes. The project also investigates the use of human iPSCs for toxicology testing; using iPSCs to generate liver, heart, nerve and kidney cells.

You might also be interested in…
Blog

ESTIV 2018 International Congress

Congress Round-Up The International Congress on in vitro Toxicology (ESTIV2018) organised by the European Society of Toxicology was held in Berlin this October 2018.  This year marks its 20th meeting, with the general theme of new approach methodologies